The COVID-19 Pandemic – News and Features

A study refutes two other studies pointing to snakes as an intermediate host and suggests that scaly, anteater-like animals called pangolins are the missing link for SARS-CoV-2 transmission between bats and humans.

Technology Networks spoke with Amelie Boulais, Vaccine Marketing Manager, Sartorius, to find out more about how Sartorius is supporting vaccine development at this critical time and the power of collaboration.

Technology Networks spoke with Dr Paul Hodgson, Associate Director of Business Development at VIDO-InterVac to learn more about their experience working with coronaviruses, the organization's manufacturing facilities, and the other antivirals and therapeutics they are currently testing in relation to COVID-19.

Researchers from the Centre for Genomic Regulation (CRG) have launched a new database to advance the international research efforts studying COVID-19.

Research published by the Linterman lab shows that the immune system of older mice can be given a helping hand by applying immunology expertise and some genital wart treatment (don’t try this at home just yet)!

Researchers found that half of the patients they treated for mild COVID-19 infection still had coronavirus for up to eight days after symptoms disappeared.

A completely new resistance gene, which is likely to counteract the newest aminoglycoside-drug plazomycin, was recently discovered by scientists at the University of Gothenburg.

Using a free computer game called "Foldit", researchers are enlisting the help of citizen scientists to design drugs to stop the coronavirus from infecting human cells.

Scientists have identified a novel group of immune cells in the lungs that are associated with the control of inflammation during viral infections, like influenza or possibly coronavirus. This discovery may help to advance the development of therapeutics to treat inflammation-related lung conditions such as bronchitis, influenza and potentially even COVID-19.

Researchers at the University of Connecticut have been working to develop a new, low-cost, CRISPR-based diagnostic platform to detect infectious diseases, including the novel coronavirus (SARS-CoV-2).